How should I document Yale‑Brown Obsessive‑Compulsive Scale – Second Edition (Y‑BOCS‑II) scoring for a 32‑year‑old female with obsessive‑compulsive disorder, including item scores, subscale totals, severity interpretation, clinical impression, and treatment plan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Y-BOCS-II Documentation Framework

Document Y-BOCS-II scores by recording all 10 individual item ratings (0–4 each), calculating obsession and compulsion subscale totals (0–20 each), reporting the total severity score (0–40), classifying severity band, noting avoidance behaviors explicitly, and linking the numerical result to a treatment decision. 1

Core Scoring Structure

  • The Y-BOCS-II contains 10 items, each rated 0 (no symptoms) to 4 (extreme symptoms), yielding a total possible score of 0–40. 2, 3
  • Items 1–5 assess obsession severity (time, interference, distress, resistance, control); items 6–10 assess compulsion severity (same domains). 2
  • Calculate and document separate subscale totals for obsessions and compulsions; a subscale score ≥14 indicates severe OCD even when only one symptom type predominates. 1

Severity Classification

  • Apply the following severity bands to the total score: 1, 4
    • 0–7: Subclinical
    • 8–15: Mild OCD
    • 16–23: Moderate OCD
    • 24–31: Severe OCD
    • ≥32: Extreme OCD
  • A total score ≥28 in adults defines treatment-refractory OCD and signals the need for intensified strategies (e.g., augmentation, neurosurgical consultation). 1

Avoidance Documentation

  • Explicitly document avoidance behaviors in a separate narrative field, because extensive avoidance of triggering situations artificially lowers Y-BOCS-II scores by reducing observable time spent on rituals. 1, 5
  • Ask: "What situations, places, or objects do you avoid to prevent obsessions or compulsions?" and record specific examples (e.g., "avoids public restrooms," "refuses to touch doorknobs"). 1
  • The Y-BOCS-II integrates avoidance into the scoring framework of individual items, so failure to probe for avoidance leads to underestimation of true severity. 2, 6

Clinical Impression and Symptom Dimensions

  • Identify and document the primary symptom dimension(s): contamination/cleaning, harm/checking, symmetry/ordering, or unacceptable/taboo thoughts (e.g., sexual-orientation obsessions). 1
  • Record the patient's level of insight using DSM-5 specifiers: good/fair insight (beliefs probably untrue), poor insight (beliefs probably true), or absent/delusional insight (beliefs completely true). 1
  • Note that sexual-orientation obsessions are intrusive, ego-dystonic thoughts—not identity crises—and are frequently misidentified by clinicians unfamiliar with OCD phenomenology. 7, 1

Treatment Plan Linked to Score

  • For moderate OCD (16–23): Initiate or continue exposure and response prevention (ERP) therapy; add an SSRI if insufficient response after 8–12 weeks of ERP. 1
  • For severe OCD (24–31): Prescribe combined SSRI + ERP concurrently to maximize symptom reduction; verify the patient is receiving OCD-specific SSRI dosing (e.g., sertraline 150–200 mg/day, fluoxetine 40–80 mg/day). 1
  • For absent/delusional insight: Augment SSRI + ERP with an atypical antipsychotic and monitor metabolic parameters (weight, glucose, lipids) and extrapyramidal symptoms. 1
  • Define clinically meaningful response as a ≥35% reduction from baseline Y-BOCS-II score; reassess every 4–8 weeks during active treatment. 5

Example Documentation (32-Year-Old Female)

Y-BOCS-II Administration Date: [Insert date]

Individual Item Scores:

  • Item 1 (Time spent on obsessions): 3

  • Item 2 (Interference from obsessions): 3

  • Item 3 (Distress from obsessions): 4

  • Item 4 (Resistance to obsessions): 2

  • Item 5 (Control over obsessions): 2

  • Obsession Subscale Total: 14/20

  • Item 6 (Time spent on compulsions): 3

  • Item 7 (Interference from compulsions): 3

  • Item 8 (Distress from compulsions): 3

  • Item 9 (Resistance to compulsions): 2

  • Item 10 (Control over compulsions): 2

  • Compulsion Subscale Total: 13/20

Total Y-BOCS-II Score: 27/40 (Severe OCD) 1

Avoidance Behaviors: Patient avoids touching doorknobs, public restrooms, and shaking hands; refuses to prepare food for family members. Avoidance reduces observable ritual time but causes significant functional impairment. 1, 6

Primary Symptom Dimension: Contamination/cleaning obsessions and washing compulsions. 1

Insight Level: Good/fair insight—patient recognizes contamination fears are probably excessive. 1

Functional Impairment: Sheehan Disability Scale: Work 7/10, Social 8/10, Family 9/10. Patient reports missing 6 workdays in the past month due to rituals. 1

Treatment Plan:

  • Continue sertraline 200 mg/day (maximum tolerated dose achieved 10 weeks ago). 1
  • Refer to OCD-specialized therapist for twice-weekly ERP sessions targeting contamination hierarchy. 1
  • Educate family to reduce accommodation behaviors (e.g., stop providing reassurance about cleanliness). 1
  • Reassess Y-BOCS-II in 8 weeks; target ≥35% reduction (goal score ≤18). 5
  • If score remains ≥28 after 12 weeks of combined treatment, consider aripiprazole augmentation. 1

Common Pitfalls

  • Do not declare treatment failure before verifying 8–12 weeks at maximum tolerated SSRI dose; OCD requires higher doses and longer trials than depression. 1
  • Do not overlook family accommodation; ask whether family members participate in rituals, provide reassurance, or modify routines, as these behaviors maintain symptoms and predict poorer outcomes. 1
  • Do not mistake compulsions for ADHD impulsivity; compulsions are anxiety-driven, ego-dystonic rituals, whereas ADHD impulsivity is ego-syntonic and not ritualistic. 1

References

Guideline

Follow‑Up Assessment and Management of Obsessive‑Compulsive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

CY-BOCS Score Interpretation Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Updated Guidance for the Children’s Yale‑Brown Obsessive‑Compulsive Scale (CY‑BOCS‑II)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

How is the Yale‑Brown Obsessive‑Compulsive Scale – Second Edition (Y‑BOCS‑II) scored and interpreted?
What is the interpretation of Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores in assessing obsessive-compulsive disorder (OCD) severity?
When assessing a patient with obsessive‑compulsive disorder, should I use the Yale‑Brown Obsessive‑Compulsive Scale (Y‑BOCS) or the revised Yale‑Brown Obsessive‑Compulsive Scale – Second Edition (Y‑BOCS‑II)?
What is the role of the Yale-Brown Obsessive Compulsive Scale (YBOCS) in assessing and treating Obsessive-Compulsive Disorder (OCD), specifically Relationship OCD?
What is the treatment for a patient with a Y-BOCS (Yale-Brown Obsessive Compulsive Scale) score of 28 indicating severe obsessive-compulsive disorder symptoms?
What is the best imaging modality to rule out an abscess in a patient with cellulitis?
What is the recommended acute management for an adult presenting with acute left‑ventricular failure (pulmonary edema, rapid onset dyspnea, hypoxia, or cardiogenic shock)?
What is Citrobacter koseri?
How should a possible tympanic membrane rupture be initially managed?
In an adult patient without contraindications (e.g., pregnancy, recent myocardial infarction, unstable angina, severe arrhythmias, nicotine hypersensitivity), can nicotine transdermal patches be used concurrently with nicotine lozenges?
I have an HSV‑1 IgG level of 55.4 IU/mL with no current oral or facial lesions—what does this result mean and is any treatment or further work‑up needed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.